- Lyell Immunopharma (NASDAQ:LYEL) registers 625,000 common shares for resale by selling stockholders.
- Shares were issued as additional merger consideration under the October 2024 merger agreement with ImmPACT Bio.
- Issuance triggered by achievement of a clinical milestone tied to ImmPACT Bio’s next-gen CAR T-cell product.
- Milestone was met, and shares issued to stockholders on July 2, 2025.
- Lyell will not receive any proceeds from the resale.
Lyell Immunopharma registers 625,000 shares for resale

Related
Alcoa CEO says Canada growth projects on pause due to Trump'...
14 minutes ago
0
3M reverses lower as adjusted organic sales growth seen as d...
41 minutes ago
0
Gold futures finish flat week as rally loses steam
1 hour ago
0
Block surges nearly 10% on S&P 500 inclusion
1 hour ago
0
RLI Q2 2025 Earnings Preview
2 hours ago
0
Beneficient receives Nasdaq listing determination notice
2 hours ago
0
Oak Valley Bancorp declares $0.30 dividend
2 hours ago
0
Playboy files for $250M mixed securities shelf
2 hours ago
0
Xcel Energy unveils expansion plans in Texas, New Mexico
2 hours ago
1
Bowen Acquisition receives Nasdaq delisting notification
2 hours ago
0
Trending
Popular
© FBT Company 2025. All rights are reserved